Literature DB >> 16781791

Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice.

Aída Zulueta1, Jorge Martín, Lisset Hermida, Mayling Alvarez, Iris Valdés, Irina Prado, Glay Chinea, Delfina Rosario, Gerardo Guillén, María G Guzmán.   

Abstract

The immunogenicity of the Envelope fragment from amino acid 284 to 426 of Dengue viruses, obtained as fusion proteins with P64k in Escherichia coli, has been previously tested by our group. Here, we studied two fusion proteins with P64k carrying the Envelope fragment from two strains of Dengue 3: H87 prototype strain (PD9) and an isolate from the Nicaragua 1994 outbreak (PD18). Sequence comparison of the Dengue Envelope fragments showed four amino acid differences. Only PD18 reacted with human antisera and induced a higher functional immune response in mice than PD9. Moreover, mice immunized with PD18 were less susceptible to Dengue 3 administered intracerebrally than those immunized with PD9. The results reveal that not all sequences of the Dengue Envelope fragment, at least in the context of P64k, are antigenic and generate a functional immune response against the native virus. This finding has direct implications for the design of vaccines based on fragments of the Envelope protein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16781791     DOI: 10.1016/j.virusres.2006.04.003

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  15 in total

1.  Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes.

Authors:  Lidice Bernardo; Osmel Fleitas; Alequis Pavón; Lisset Hermida; Gerardo Guillén; Maria G Guzman
Journal:  Clin Vaccine Immunol       Date:  2009-09-02

2.  An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.

Authors:  Laura J White; Carlos A Sariol; Melissa D Mattocks; Wahala Wahala M P B; Vorraphun Yingsiwaphat; Martha L Collier; Jill Whitley; Rochelle Mikkelsen; Idia V Rodriguez; Melween I Martinez; Aravinda de Silva; Robert E Johnston
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

3.  Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.

Authors:  Julia C Frei; Ariel S Wirchnianski; Jennifer Govero; Olivia Vergnolle; Kimberly A Dowd; Theodore C Pierson; Margaret Kielian; Mark E Girvin; Michael S Diamond; Jonathan R Lai
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

4.  Natural strain variation and antibody neutralization of dengue serotype 3 viruses.

Authors:  Wahala M P B Wahala; Eric F Donaldson; Ruklanthi de Alwis; Mary Ann Accavitti-Loper; Ralph S Baric; Aravinda M de Silva
Journal:  PLoS Pathog       Date:  2010-03-19       Impact factor: 6.823

5.  Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity.

Authors:  Anna P Durbin; Sandra V Mayer; Shannan L Rossi; Irma Y Amaya-Larios; Jose Ramos-Castaneda; Eng Eong Ooi; M Jane Cardosa; Jorge L Munoz-Jordan; Robert B Tesh; William B Messer; Scott C Weaver; Nikos Vasilakis
Journal:  Virology       Date:  2013-02-26       Impact factor: 3.616

6.  Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.

Authors:  Jedhan U Galula; Wen-Fan Shen; Shih-Te Chuang; Gwong-Jen J Chang; Day-Yu Chao
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

7.  Simplifying complex sequence information: a PCP-consensus protein binds antibodies against all four Dengue serotypes.

Authors:  David M Bowen; Jessica A Lewis; Wenzhe Lu; Catherine H Schein
Journal:  Vaccine       Date:  2012-07-31       Impact factor: 3.641

8.  Phenotypic characterization of patient dengue virus isolates in BALB/c mice differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome.

Authors:  Anne Tuiskunen; Maria Wahlström; Jakob Bergström; Philippe Buchy; Isabelle Leparc-Goffart; Ake Lundkvist
Journal:  Virol J       Date:  2011-08-11       Impact factor: 4.099

Review 9.  The human antibody response to dengue virus infection.

Authors:  Wahala M P B Wahala; Aravinda M de Silva
Journal:  Viruses       Date:  2011-11-25       Impact factor: 5.048

10.  Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization.

Authors:  William B Messer; Boyd Yount; Kari E Hacker; Eric F Donaldson; Jeremy P Huynh; Aravinda M de Silva; Ralph S Baric
Journal:  PLoS Negl Trop Dis       Date:  2012-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.